Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Lumasiran in Healthy Adults and PH1 Patients
NCT02706886Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Jan 2019
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
Phase 2, randomised, single-blind trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) (9 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events up to 546 days. Started Mar 2016; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT02706886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706886.